close

Covance Inc., a drug development services company, provides early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries worldwide. Its early stage development services include preclinical services, such as toxicology, pharmaceutical and nutritional chemistry, polyclonal and monoclonal antibody services, and bioanalytical services; and clinical pharmacology services, including first-in-human trials of new pharmaceuticals. The company's late stage development services include central laboratory services, including biomarker services to biotechnology and pharmaceutical customers; clinical development services comprising the full management of Phase II and III clinical studies, study design and modeling, study orchestration, trial logistics, enablement of study site performance, clinical data management and biostatistical analysis, and medical writing and regulatory services; clinical trial support services consisting of cardiac safety and interactive voice and Web response services; and commercialization services, such as periapproval services and market access services. It also offers laboratory testing services to the chemical, agrochemical, and food industries. The company was founded in 1987 and is based in Princeton, New Jersey.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	47.57
Volume	(mio) 1.05
Volume Avg	801958
52 Week High	63.86
52 Week Low	42.02
PE	22.62
PE (group average)	39
EPS Year	2.16
EPS change Q/Q	19.57%
EPS change Q/Q Yr ago	-11.29%
EPS change Q/Q next Q est	-14.06%
EPS change Y/Y	168.63%
REV change Q/Q	1.54%
REV change Q/Q Yr ago	4.46%
EPS next Q est	0.64
EPS next Y est	2.85
Divident Annual	0.00
Dividend Yield	0%